天壇生物(600161.SH):擬放棄收購派林生物商業機會
格隆匯8月4日丨天壇生物(600161.SH)公佈,近期,公司收到控股股東中國生物《關於投資商業機會的通知函》,本次交易標的為派林生物控股股東勝幫英豪持有的其全部21.03%股份(簡稱“商業機會”)。由於派林生物主營業務為血液製品的研究、開發、生產和銷售,與公司主營業務構成同業競爭,中國生物根據2017年12月1日出具的《關於避免與北京天壇生物製品股份有限公司同業競爭的承諾函》,將其獲得的與公司主營業務構成實質性同業競爭的新業務機會書面通知公司。
經審慎分析研判,公司擬放棄收購派林生物商業機會。公司放棄收購派林生物商業機會後,中國生物將從整體發展戰略出發,實施派林生物商業機會的收購,中國生物完成本次收購後,將就新增同業競爭問題的解決時限、基本路徑等做出進一步承諾,公司將在收到相關承諾文件後及時履行信息披露義務。中國生物已根據前次避免同業競爭承諾函,及時向公司書面吿知商業機會,已履行承諾函中的義務,不存在違反承諾的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.